Gene Therapy is the use of genetic information inside a therapeutic viral vector carrier that actively replaces and repairs “damaged” genes that cause disease or disability in a patient. GT is the most promising new, curative therapy for conditions like inherited disorders, some treatment resistant cancers and incurable viral infections like Hepatitis C or HIV.
The last 15 years have seen gene therapy graduate from an experimental, research approach to an approved treatment modality, with over 1800 gene therapy trials initiated or approved worldwide between 2015 and 2017. Especially 2017 has been a landmark year for gene therapy, with several licensed therapies now available to treat patients. Despite its recent success, there are still significant challenges. The target site to which a therapeutic viral vector delivers its payload into the genome of a patient can be missed with devastating consequences: the gene defect remains uncured and the “off-site” activity of the satellite gene can cause additional, sometimes fatal pathologies genotoxicity. Treatments for several genetic disorders are available including cancer, however, no standardised platform has been available to test safety, which is concerning following the development of leukaemia in several children treated for X-linked immunodeficiency by this therapy. A standardised test to determine and quantify the risk of genotoxicity for therapeutic viral vectors is of major need and importance.
Testavec is developing a standardised, clinically validated and CE marked gene therapy therapeutic viral vector safety assay, based on sequential viral infection in an induced Pluripotent Stem Cell (iPSc) platform to scan and read-out gene expression of genes targeted by therapeutic viral vector integration.
The test platform is designed to
i) certify gene therapy therapeutic viral vector safety in advance of use in clinical trials of novel “genotoxicity”, and
ii) assess tolerance of gene therapy therapeutic viral vector in individual patients.
The aim of the Testavec genotox platform is to become the mandated certification process of the regulatory bodies as at present such a safety predicate does not exist for this new class of therapeutics.